Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30723493 | 0.77 | HTR2A (0.33) | HTR2AHTR2CHTR2BTLR8REN | |
| SCHEMBL25254061 | 0.73 | MBOAT4 (0.32) | MBOAT4HTR2AHTR2CHTR2B | |
| SCHEMBL16703136 | 0.71 | SCN9A (0.33) | HTR2AHTR2CHTR2BRENCTSD | |
| SCHEMBL34471462 | 0.70 | GRM2 (0.30) | — | |
| SCHEMBL34471808 | 0.69 | ACACB (0.31) | — | |
| SCHEMBL18205343 | 0.67 | PDE8A (0.32) | — | |
| SCHEMBL25244277 | 0.67 | GRM4 (0.38) | — | |
| SCHEMBL21608759 | 0.67 | BACE1 (0.33) | HTR2AHTR2CHTR2BTLR8REN | |
| SCHEMBL22235500 | 0.67 | HTT (0.46) | HTR2AHTR2CHTR2BTLR8 | |
| SCHEMBL29778825 | 0.67 | BACE1 (0.33) | HTR2AHTR2CHTR2BTLR8REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-4188930-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | CYP11B2, SDHA, UGT2B7 | MBOAT4 3260/4885S1PR4 2772/4885HTR2A 1384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.